Technical Analysis for CASI - CASI Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 5.40 -1.82% -0.10
CASI closed down 1.82 percent on Monday, July 1, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Wide Range Bar Range Expansion -1.82%
Wide Bands Range Expansion -1.82%

   Recent Intraday Alerts

Alert Time
Down 5% about 7 hours ago
Down 3% about 7 hours ago
Down 2 % about 7 hours ago
Down 1% about 7 hours ago
Up 2% about 7 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CASI Pharmaceuticals, Inc. Description

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Pharmaceutical Disease Solid Tumors Autoimmune Disease Cancer Treatment Treatment Of Cancer Ovarian Cancer Leukemia Multiple Myeloma Platinum Stage Pharmaceutical Advanced Solid Tumors Cyclacel Cell Cycle Pyrrolidines

Is CASI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.4757
52 Week Low 1.9
Average Volume 274,932
200-Day Moving Average 4.29
50-Day Moving Average 3.21
20-Day Moving Average 3.67
10-Day Moving Average 3.95
Average True Range 0.50
RSI (14) 73.12
ADX 26.7
+DI 43.34
-DI 11.57
Chandelier Exit (Long, 3 ATRs) 4.18
Chandelier Exit (Short, 3 ATRs) 4.12
Upper Bollinger Bands 5.14
Lower Bollinger Band 2.21
Percent B (%b) 1.09
BandWidth 79.88
MACD Line 0.43
MACD Signal Line 0.20
MACD Histogram 0.2272
Fundamentals Value
Market Cap 71.94 Million
Num Shares 13.3 Million
EPS -3.00
Price-to-Earnings (P/E) Ratio -1.80
Price-to-Sales 2.03
Price-to-Book 2.89
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.12
Resistance 3 (R3) 6.12 5.89 6.00
Resistance 2 (R2) 5.89 5.70 5.89 5.96
Resistance 1 (R1) 5.64 5.59 5.77 5.64 5.92
Pivot Point 5.41 5.41 5.47 5.41 5.41
Support 1 (S1) 5.16 5.22 5.29 5.16 4.88
Support 2 (S2) 4.93 5.11 4.93 4.84
Support 3 (S3) 4.68 4.93 4.80
Support 4 (S4) 4.68